Literature DB >> 2127381

Metrifonate in the control of urinary schistosomiasis in Zanzibar.

A F Mgeni1, U M Kisumku, F S McCullough, H Dixon, S S Yoon, K E Mott.   

Abstract

Selective population chemotherapy using three doses of metrifonate (7.5 mg/kg body weight each time) at two-week intervals was assessed in an entire community in Kinyasini district in Zanzibar, United Republic of Tanzania. The objectives of the study were to (1) reduce the prevalence of heavy infections (defined as greater than or equal to 50 S. haematobium eggs per 10 ml of urine) by 75% in two years, and (2) reduce the overall prevalence of infection by 50% in two years. A total of 4113 people were examined at least once during the two-year period. In the initial survey the highest proportion of infected individuals was in the 10-14-year age group, and in all subsequent surveys in the 5-9-year age group. The age group with the highest proportion of heavily infected individuals was 5-9 years for all surveys. The overall reduction of prevalence of infection from survey 1 to survey 4 was 52.9% and the prevalence of heavy infection was reduced by 62.2%. The conversion rates (negative to positive in two consecutive surveys) were highest in the longest interval of 12 months and the rates of reversion (positive to negative in two consecutive surveys, without a history of treatment) were highest in the shortest interval of 4 months. Some statistically significant relationships were observed between the number of doses and the egg reduction rates. However, for the egg-negative rates, no statistically significant relationship was observed. In the 4-month interval a 67.6% egg-negative rate was observed among those who took at least one dose; with the 12-month interval a 48.3% egg-negative rate was observed. Thus, selective population chemotherapy with metrifonate was shown to reduce the prevalence and intensity of infection due to S. haematobium over a 24-month period.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2127381      PMCID: PMC2393165     

Source DB:  PubMed          Journal:  Bull World Health Organ        ISSN: 0042-9686            Impact factor:   9.408


  12 in total

1.  Cost and effectiveness of different approaches to schistosomiasis control in Africa.

Authors:  R Korte; B Schmidt-Ehry; A A Kielmann; U K Brinkmann
Journal:  Trop Med Parasitol       Date:  1986-06

2.  Treatment of urinary schistosomiasis. Practice and theory.

Authors:  D M Forsyth; C Rashid
Journal:  Lancet       Date:  1967-01-21       Impact factor: 79.321

3.  Treatment of urinary schistosomiasis with trichlorophone.

Authors:  D M Forsyth; C Rashid
Journal:  Lancet       Date:  1967-10-28       Impact factor: 79.321

4.  [Effectiveness of 3 doses of metrifonate in the treatment of urinary bilharziasis in Senegal].

Authors:  S Diallo; J F Ceccon; A Victorius; F Diouf; O N'dir
Journal:  Dakar Med       Date:  1983

5.  Use of metrifonate for selective population chemotherapy against urinary schistosomiasis in an endemic area at Mwanza, Tanzania.

Authors:  J B Rugemalila; V M Eyakuze
Journal:  East Afr Med J       Date:  1981-01

6.  Long-term efficacy of single-dose oral treatment in schistosomiasis haematobium.

Authors:  R N Pugh; C H Teesdale
Journal:  Trans R Soc Trop Med Hyg       Date:  1984       Impact factor: 2.184

7.  Chemotherapy-based control of schistosomiasis haematobia. I. Metrifonate versus praziquantel in control of intensity and prevalence of infection.

Authors:  C H King; G Lombardi; C Lombardi; R Greenblatt; S Hodder; H Kinyanjui; J Ouma; O Odiambo; P J Bryan; J Muruka
Journal:  Am J Trop Med Hyg       Date:  1988-09       Impact factor: 2.345

Review 8.  Clinical experience with metrifonate. Review with emphasis on its use in endemic areas.

Authors:  H Feldmeier; E Doehring
Journal:  Acta Trop       Date:  1987-09       Impact factor: 3.112

9.  Eighteen-month follow-up on the treatment of urinary schistosomiasis with a single dose of metrifonate.

Authors:  S A Tswana; P R Mason
Journal:  Am J Trop Med Hyg       Date:  1985-07       Impact factor: 2.345

10.  Metrifonate in urinary schistosomiasis.

Authors:  A Davis; D R Bailey
Journal:  Bull World Health Organ       Date:  1969       Impact factor: 9.408

View more
  14 in total

1.  Transmission and diversity of Schistosoma haematobium and S. bovis and their freshwater intermediate snail hosts Bulinus globosus and B. nasutus in the Zanzibar Archipelago, United Republic of Tanzania.

Authors:  Tom Pennance; Shaali Makame Ame; Amour Khamis Amour; Khamis Rashid Suleiman; Mtumweni Ali Muhsin; Fatma Kabole; Said Mohammed Ali; John Archer; Fiona Allan; Aidan Emery; Muriel Rabone; Stefanie Knopp; David Rollinson; Joanne Cable; Bonnie L Webster
Journal:  PLoS Negl Trop Dis       Date:  2022-07-05

2.  Parasitic infections in Pemba Island school children.

Authors:  M Albonico; H M Chwaya; A Montresor; R J Stolfzfus; J M Tielsch; K S Alawi; L Savioli
Journal:  East Afr Med J       Date:  1997-05

3.  Community Knowledge, Perceptions, and Practices Associated with Urogenital Schistosomiasis among School-Aged Children in Zanzibar, United Republic of Tanzania.

Authors:  Bobbie Person; Said M Ali; Faiza M A'Kadir; Jamal N Ali; Ulfat A Mohammed; Khalfan A Mohammed; David Rollinson; Stefanie Knopp
Journal:  PLoS Negl Trop Dis       Date:  2016-07-11

4.  Increasing the reach: Involving local Muslim religious teachers in a behavioral intervention to eliminate urogenital schistosomiasis in Zanzibar.

Authors:  Mike Celone; Bobbie Person; Said M Ali; Jameelat H Lyimo; Ulfat A Mohammed; Alippo N Khamis; Yussra S Mohammed; Khalfan A Mohammed; David Rollinson; Stefanie Knopp
Journal:  Acta Trop       Date:  2016-08-03       Impact factor: 3.112

5.  Praziquantel coverage in schools and communities targeted for the elimination of urogenital schistosomiasis in Zanzibar: a cross-sectional survey.

Authors:  Stefanie Knopp; Bobbie Person; Shaali M Ame; Said M Ali; Juma Muhsin; Saleh Juma; Iddi S Khamis; Muriel Rabone; Lynsey Blair; Alan Fenwick; Khalfan A Mohammed; David Rollinson
Journal:  Parasit Vectors       Date:  2016-01-04       Impact factor: 3.876

6.  Performance of a real-time PCR approach for diagnosing Schistosoma haematobium infections of different intensity in urine samples from Zanzibar.

Authors:  Dominique Keller; Julian Rothen; Jean-Pierre Dangy; Corina Saner; Claudia Daubenberger; Fiona Allan; Shaali M Ame; Said M Ali; Fatma Kabole; Jan Hattendorf; David Rollinson; Ralf Seyfarth; Stefanie Knopp
Journal:  Infect Dis Poverty       Date:  2020-09-04       Impact factor: 4.520

Review 7.  Epidemiology and control of human schistosomiasis in Tanzania.

Authors:  Humphrey D Mazigo; Fred Nuwaha; Safari M Kinung'hi; Domenica Morona; Angela Pinot de Moira; Shona Wilson; Jorg Heukelbach; David W Dunne
Journal:  Parasit Vectors       Date:  2012-11-28       Impact factor: 3.876

8.  Study and implementation of urogenital schistosomiasis elimination in Zanzibar (Unguja and Pemba islands) using an integrated multidisciplinary approach.

Authors:  Stefanie Knopp; Khalfan A Mohammed; Said M Ali; I Simba Khamis; Shaali M Ame; Marco Albonico; Anouk Gouvras; Alan Fenwick; Lorenzo Savioli; Daniel G Colley; Jürg Utzinger; Bobbie Person; David Rollinson
Journal:  BMC Public Health       Date:  2012-10-30       Impact factor: 3.295

9.  Elimination of schistosomiasis transmission in Zanzibar: baseline findings before the onset of a randomized intervention trial.

Authors:  Stefanie Knopp; Bobbie Person; Shaali M Ame; Khalfan A Mohammed; Said M Ali; I Simba Khamis; Muriel Rabone; Fiona Allan; Anouk Gouvras; Lynsey Blair; Alan Fenwick; Jürg Utzinger; David Rollinson
Journal:  PLoS Negl Trop Dis       Date:  2013-10-17

10.  Urogenital schistosomiasis elimination in Zanzibar: accuracy of urine filtration and haematuria reagent strips for diagnosing light intensity Schistosoma haematobium infections.

Authors:  Stefanie Knopp; Shaali M Ame; Jan Hattendorf; Said M Ali; Iddi S Khamis; Faki Bakar; Mwanaidi A Khamis; Bobbie Person; Fatma Kabole; David Rollinson
Journal:  Parasit Vectors       Date:  2018-10-23       Impact factor: 3.876

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.